Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome

Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome

Cong Shi,1,* Shengping Gong,2,* An Wu,3 Tingting Niu,1 Ningning Wu,1 Yi Zhang,1 Guifang Ouyang,3 Qitian Mu1 1Laboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, People’s Republic of China; 2Cancer Radiotherapy and Chemotherapy Center, Ningbo First Hospit...

Full description

Bibliographic Details
Main Authors: Shi C, Gong S, Wu A, Niu T, Wu N, Zhang Y, Ouyang G, Mu Q
Format: Article
Language:English
Published: Dove Medical Press 2022-06-01
Series:Cancer Management and Research
Subjects:
myelodysplastic syndrome
ipss-r
prognostic
overall survival
fibrinogen.
Online Access:https://www.dovepress.com/hyperfibrinogenemia-as-a-poor-prognostic-indicator-in-myelodysplastic--peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/hyperfibrinogenemia-as-a-poor-prognostic-indicator-in-myelodysplastic--peer-reviewed-fulltext-article-CMAR

Similar Items